Thomas N. Sato (佐藤 匠徳) is a prominent Japanese educator, entrepreneur, and biologist, whose research focuses on understanding molecular basis of cancer, cardiac disease and metabolic diseases by using a number of animal models including mice, zebrafish and fruit flies. He is also working to invent next-generation therapeutics for human diseases based on the stochastic basis of life and disease. He is currently director of the Thomas N. Sato BioMEC-X Laboratories at the Advanced Telecommunications Research Institute International (ATR) in Kyoto,[1] research director of the ERATO Sato Live Bio-forecasting project JST in Kyoto, scientific founder and chair of board of directors Karydo TherapeutiX, Inc,[2] professor of Virtual Human InformatiX Clinic in Nara, and affiliate professor at Centenary Institute in Sydney, Australia.[3][4][5] He is also a triathlete who competes at Ironman distance including Ironman Lake Placid, Ironman Japan, Ironman Coeur d’Alene.

Life

Works

Awards

  • National Science Contest for Elementary School Students, 1st-place winner, Japan, 1973
  • Cold Spring Harbor Summer Fellowship, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY 1998
  • American Heart Association, Established Investigator Award, USA 1998-2003
  • Japanese Endocrinology and Cardiovascular Society, Jokichi Takamine Research Award, Japan 2005
  • Listed among top 1% most cited authors for journals in Molecular Biology and Genetics 2006
  • Scientific Advisory Board Member, Surface Logix, Inc. 2006-2008

References

  1. "The Thomas N. Sato Bio-MEC-X Laboratories". www.tnsl.atr.jp.
  2. "Scientific Founder English | Karydo TherapeutiX, Inc" (in Japanese). Retrieved 28 February 2020.
  3. "Laboratory of Biodynamics and Integrative Biology". Archived from the original on 2013-07-05. Retrieved 2013-07-23.
  4. "NAIST-Biological Science, Biodynamics and Integrative Biology". Archived from the original on 2013-07-23. Retrieved 2013-07-23.
  5. "The 1st International Symposium on Human InformatiX – X-Dimensional Human Informatics and Biology" (in Japanese). Retrieved 28 February 2020.
  6. Sato TN, et al. (October 1993). "Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system". Proc. Natl. Acad. Sci. USA. 90 (20): 9355–9358. Bibcode:1993PNAS...90.9355S. doi:10.1073/pnas.90.20.9355. PMC 47566. PMID 8415706.
  7. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD (Dec 1996). "Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis". Cell. 87 (7): 1171–1180. doi:10.1016/S0092-8674(00)81813-9. PMID 8980224.
  8. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD (July 1997). "Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis". Science. 277 (5322): 55–60. doi:10.1126/science.277.5322.55. PMID 9204896.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.